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Can early treatment of twitcher mice with high dose AAVrh10-GALC 
eliminate the need for BMT?  
Mohammad A Rafi* ID , Paola Luzi, David A Wenger ID
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Introduction
Globoid cell leukodystrophy (GLD) or Krabbe disease 
(KD) is a lysosomal disorder caused by the deficiency 
of galactocerebrosidase (GALC) activity.1 The disease is 
inherited in an autosomal recessive manner and presents 
in the most severe infantile form by 6 months of age, 
followed by death usually by 2 years of age.2 While the 
infantile form of the disease is most common, later onset 
and adult patients with KD are also diagnosed. In the 
absence of GALC activity not only galactosylceramide 
(galcer), an important component of myelin, cannot be 
degraded but galactosylsphingosine or psychosine also 
accumulates to a toxic level.3-5
There are several animal models for this disease, 
including mouse, dog, and monkey models that are 
being used for the treatment trials.6-8 Twitcher (twi) 
mouse, the murine model of KD, has been extensively 
used to understand the pathogenesis of this disease and 
in many treatment trials.9 This has resulted in various 
outcomes in improving the myelination process and 
extension of life. However, none of these approaches has 
resulted in a complete correction of the clinical features 
and pathological aspects of the disease. For complete 
correction of the disease, adequate GALC activity needs 
to be delivered to the CNS and PNS. Gene therapy seems 
the most promising in addressing this need, but the blood 
brain barrier (BBB) remains an issue.10-15 
Hematopoietic stem cell transplantation (HSCT) is 
currently the “standard of care” for human patients.16,17 
Besides providing some GALC enzyme to different CNS 
cell types, it may play an anti-inflammatory role. GALC-
expressing macrophages from transplanted HSCs play 
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Introduction: Krabbe disease (KD) is an autosomal recessive 
disorder caused by mutations in the galactocerebrosidase (GALC) 
gene resulting in neuro-inflammation and defective myelination 
in the central and peripheral nervous systems. Most infantile 
patients present with clinical features before six months of age and 
die before two years of age. The only treatment available for pre-
symptomatic or mildly affected individuals is hematopoietic stem 
cell transplantation (HSCT). In the animal models, combining 
bone marrow transplantation (BMT) with gene therapy has shown 
the best results in disease outcome. In this study, we examine the 
outcome of gene therapy alone.
Methods: Twitcher (twi) mice used in the study, have a W339X mutation in the GALC gene. 
Genotype identification of the mice was performed shortly after birth or post-natal day 1 (PND1), 
using polymerase chain reaction on the toe clips followed by restriction enzyme digestion and 
electrophoresis. Eight or nine-day-old affected mice were used for gene therapy treatment alone or 
combined with BMT. While iv injection of 4 × 1013 gc/kg of body weight of viral vector was used 
originally, different viral titers were also used without BMT to evaluate their outcomes.
Results: When the standard viral dose was increased four- and ten-fold (4X and 10X) without 
BMT, the lifespans were increased significantly. Without BMT the affected mice were fertile, had 
the same weight and appearance as wild type mice and had normal strength and gait. The brains 
showed no staining for CD68, a marker for activated microglia/macrophages, and less astrogliosis 
than untreated twi mice. 
Conclusion: Our results demonstrate that, it may be possible to treat human KD patients with high 
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sacrificed at different time points for analysis. If deemed 
moribund (inactive and with unexpected weight loss) the 
mice were euthanatized by carbon dioxide and the age was 
recorded.
Generation of AAVrh10-mGALC vector 
Construction of the AAVrh10-mGALC vector was 
previously reported.13 Briefly, pCB7plasmid, which is an 
enhanced version of AAV2 vector, was received from the 
Institute for Human Gene Therapy at the University of 
Pennsylvania. Murine GALC cDNA was cloned into EcoRI 
site of this plasmid, downstream from the human CMV-
enhancer/chicken β-actin hybrid promoter. The integrity 
of the ITRs was confirmed by sequencing and restriction 
enzyme analysis using SmaI and NcoI. The functionality of 
the construct was verified by in vitro cell transfection and 
measurement of GALC enzyme activity. Viral packaging 
and purification of the product were accomplished by the 
Institute for Human Gene Therapy and the vector was 
called AAVrh10-mGALC.12,13 Viral titer was determined 
by PCR of the simian virus 40 poly(A) sequence.31,32 The 
viral titer of the vector batch of AAVrh10-mGALC in use 
is 6×1013 genomic equivalents/mL. 
Viral delivery 
Viral injections were carried out on a light box to facilitate 
visualizing the tail vein. The young mice were cryo-
anesthetized on ice before the injections. Iv injection was 
done through the tail vein using a 28G insulin syringe.28 
The success of injection was verified by noting blanching 
of the vein.12 After the injection, pups were warmed and 
returned to their cage. Mice that died within a few days 
of the injection (less than 10%) were not included in the 
study.
Bone marrow transplantation (BMT) 
The methodology for BM preparation and BMT was 
previously described.28 Briefly, BMT recipient mice were 
myelo-suppressed using busulfan (Sigma-Aldrich, St. 
Louis, MO, USA). A 3 mg/mL solution of busulfan was 
prepared by initially dissolving it in dimethyl sulfoxide 
(Sigma-Aldrich) and adding sterile phosphate-buffered 
saline to bring the final concentration to 30%. Eight or 
nine-day-old affected mice were weighed, and 30 mg/
kg of body weight of the busulfan solution was injected 
intraperitoneally (ip). BM cells from the donor mice were 
obtained by flushing tibiae and femora using ice-cold 
Hepes buffered Hanks’ balanced salt solution (Mediatech, 
Manassas, VA, USA). The cells were counted, centrifuged, 
and resuspended in Dulbecco's modified Eagle's medium 
(Sigma-Aldrich). Twenty-four hours after busulfan 
injection, mice received an ip injection of 3–4 × 107 BM 
cells in a total volume of 0.2 mL. For at least two weeks 
after BMT, mice were provided with drinking water 
containing 500 μg/mL Neomycin (Sigma-Aldrich). Mice 
that received BMT and died less than PND30 were not 
pivotal role in cleaning up the undegraded myelin debris 
and content of the globoid cells.18 In animal models 
of the disease, BMT has shown a synergistic effect 
when combined with other treatment strategies.9 The 
mechanism of such synergistic effect has also been the 
subject of several studies.19,20 
While the lack of GALC activity in the CNS and PNS 
is the main cause of the disease, inflammation within the 
nervous system is also a characteristic of KD.21 We have 
previously highlighted the anti-inflammatory role of BMT 
in murine model of this disease.22 In the current article, 
we assess the abilities of bone marrow (BM) cells and 
AAVrh10-mGALC to deliver GALC activity to critical 
tissues and their ability to prevent or decrease neuro-
inflammation and extend the lives of the treated mice. An 
increase of GALC activity in brain following BMT was 
originally reported by several authors.23-26 However, the 
anti-inflammatory role of BM cells in the treatment of the 
KD may have been overstated in past decades while their 
GALC-supplying capacity has been understated.20,27,28 
Following our recent publication on the effect of viral dose 
and timing of treatment of twi mice,29 we were interested 
in exploring the effect of high viral dose alone in their 
treatment. The results demonstrate that early gene therapy 
at a sufficiently high dose can supply high GALC activity 
to the brain and other tissues and possibly prevent neuro-
inflammation before it has started. In the current paper, 
besides iv injection of our standard viral dose (4 × 1013 gc/
kg of body weight, called 1X dose), we have increased viral 
dose four times (4X = 1.6 × 1014 gc/kg of body weight) 
and ten times (10X = 4 × 1014 gc/kg of body weight) alone 
or combined with BMT. The results could indicate that 
iv injection of AAVrh10-mGALC alone supplied at high 
dose at an early time point could be successful in treating 
human patients without the need for HSCT. 
Materials and Methods 
Animal procedures 
All studies in mice were completed in accordance with 
approved protocols from the Institutional Animal Care 
and Use Committee (IACUC) at Jefferson Medical College. 
Twi mice used in the study were originally obtained from 
the Jackson Laboratory. These mice are in the C57BL/6 
background and have a W339X mutation in the GALC 
gene. Genotype identification of the mice was performed 
immediately after birth or on post-natal day 1 (PND1)
using polymerase chain reaction (PCR) as previously 
described.12,30 Toe clips were used for DNA extraction 
and genotyping. PCR products were digested with EcoRV 
restriction enzyme and analyzed by electrophoresis on 
2.5% MetaPhor agarose gel (Lonza Inc. Allendale, NJ, 
USA). Treated mice were monitored daily for the first 
week after the treatment was started and any abnormal 
signs related to the procedure was noted. Body weight 
was recorded weekly throughout their lives. Treated mice 
were allowed to survive as long as humanely possible or 
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included in these studies. Initially BM cells from non-
carrier donors were used, but in some later studies BM 
cells from carrier mice were also used.
Preparation of BM cells for GALC activity test 
To harvest BM cells from treated or untreated twi mice, 
wild type and heterozygote mice, cell isolation steps for 
BMT were followed as previously described.28 Briefly, BM 
cells were harvested by flushing tibiae and femora using 
ice-cold Hepes buffered Hanks’ balanced salt solution 
(Mediatech, Manassas, VA, USA). 28-G sterile needle were 
used for rinsing the bones. Collected cells were filtered 
through a 70-µm nylon web to extract the maximum 
quantity of BM cells, rinsed repeatedly with phosphate 
buffered saline (PBS) (Sigma-Aldrich), centrifuged and 
resuspended in 1 mL of Dulbecco's modified Eagle's 
medium.
Preparation of BM-derived monocytes/macrophages
BM cells were prepared as described above. To differentiate 
these cells towards monocytes the protocol proposed by 
Wagner et al33 was followed. Harvested cells were counted 
and seeded on 6-well ultra-low-attachment surface plates 
to prevent permanent adhesion to the bottom of the 
plate on a concentration of 106 cells per ml with up to 6 
ml per well. Plates were supplemented with 20 ng/mL 
macrophage colony stimulating factor (M-CSF) (Sigma-
Aldrich) to promote cell differentiation. The 6-well plates 
were incubated at 37°C and 5% carbon dioxide for 5 days 
and observed daily. After 5 days, 60%-80% of the cells 
were expected to be differentiated to monocytes. 
Harvesting the cultured BM cells and tail vein injection
Cells were harvested in ice-cold PBS containing 0.5% 
bovine serum albumin (BSA) (Sigma-Aldrich) and 2-mM 
EDTA (Sigma-Aldrich). kept in 4°C by gentle pipetting 
and detaching with cold harvesting solution. Cells were 
counted and suspended in 0.9% NaCl at a concentration 
of 10 × 106/mL. 
Preparation of indomethacin solution
Indomethacin (Sigma-Aldrich) was dissolved in 
polyethylene glycol/Tween 20 (Sigma-Aldrich) (95:5 v/v) 
at a concentration of 0.4 mg/mL, then, diluted to 1:200 or 
1:100 in drinking water to have 2 ug/mL and 4 ug/mL. The 
drinking water was changed twice a week. 
Tissue preparation for GALC assay 
Tissues from treated and untreated mice were removed 
immediately after carbon dioxide euthanasia. The tissues 
were immediately homogenized in distilled water using a 
Polytron apparatus (Brinkmann Instruments, Westbury, 
NY, USA) or frozen quickly and stored at −80°C. Protein 
concentration was determined following the method of 
Lowry et al.34 GALC activity was measured using [3H]
galactosylceramide substrate, according to our published 
method.35 GALC activity was expressed as nmol substrate 
hydrolyzed/h/mg protein. 
Behavioral studies 
Treated mice were weighed and examined for any signs 
of tremor, weakness, or gait disturbance daily during 
weekdays. Some of these mice were subjected to evaluation 
of their walking pattern and capability to hang upside 
down from a wire screen.
Walking pattern 
A blind tunnel made from a polyvinyl chloride pipe with 
34 cm length, 4 cm wide, and 3 cm high was used to record 
mice footprints. The front paws of the mice were dipped 
in nontoxic red food color, and back paws in blue food 
color. The mouse to be evaluate was placed at one of the 
tunnel’s end on a blank paper so that it could walk down 
the tunnel towards the light source. The piece of paper 
with the colored paw prints was retained for comparative 
analysis. An 80-day-old normal mouse and 42-day-old 
untreated affected mouse were used as the controls.
Wire hanging test
Hanging test was used to assess strength and coordination. 
The mouse was placed on top of a wired mesh that was 
slowly turned over and maintained horizontally 35 cm 
above a thick layer of soft bedding. The length of time 
until the mice fell from the wire was recorded. Each 
testing consisted of three trials with one-minute intervals 
from which the timing scores were averaged. The ability 
to hang upside down and move around for 90 seconds 
was considered normal. Wild-type mice of different ages 
were able to hang and move around for at least 90 seconds. 
Untreated twi mice were unable to hang for any length of 
time after 25 days of age. 
Immunohistochemistry 
Frozen brain sections were thawed at room temperature and 
fixed for 15 minutes in freshly made 4% paraformaldehyde 
(PFA)/PBS. These tissues were permeabilized with 0.5% 
Triton X-100 for 10 minutes then treated with blocking 
reagent from Vector Laboratories (Burlingame, CA) for one 
hour. Tissues were then incubated with the rat anti-CD68 
(BioRad, Hercules, CA) or mouse anti-GFAP (Millipore, 
MA, USA) for 90 minutes at room temperature to label 
macrophages/microglia and astrocytes. The targeted 
antigens were visualized by incubating the sections with 
the secondary anti-rabbit or anti-rat antibodies (Alexa 
488 from Molecular Probes, Eugene, OR, USA) for 2 
hours at 25°C. The immunostained slides were mounted 
with Vectashield mounting medium containing DAPI 
(Vector Laboratories, Burlingame, CA, USA) as a nuclear 
marker. Although coronal sections from the entire brain 
were monitored, most sections studied were from the 
cortex area.
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Statistical analysis 
Survival analysis was performed using GraphPad Prism 7.0 
software (GraphPad Software Inc., San Diego, CA, USA). 
The survival curves were analyzed using the log-rank 
(Mantel-Cox) test. (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001).
Results
Evaluating the effects of treating twi mice with BM cells 
from wild-type and heterozygous mice plus AAVrh10-
mGALC
The current belief about the role of BM cells in the 
treatment of twi mice and human KD patients is that 
these cells supply some GALC activity to the central and 
peripheral nervous system (CNS and PNS) in addition to 
their role in preventing neuro-inflammation. We found 
this to be in contrast with our recent findings when BM 
cells from heterozygous donors were used in combination 
with gene therapy.29 Treating mice with BM cells from 
wild-type donors and a 1X viral dose (4 ×1013 gc/kg) 
results in a longer lifespan compared to mice receiving the 
same viral dose and BM cells from heterozygous mice. In 
addition, the survival rate of mice treated with BM cells 
from heterozygous mice along with a 1X viral dose, is 
comparable to the survival rate of the mice treated with 
BM cells from wild-type mice but receiving half of the 
viral dose (2 × 1013 gc/kg) (Fig. 1). Such findings show the 
importance of GALC activity delivered by BM cells in the 
twi mouse treated with combined therapy. Studies have 
shown no significant histological or behavioral differences 
between wild-type and heterozygous mice although 
heterozygous mice may have decreased ability to repair 
myelin following treatment with cuprizone.36, 37 
We examined the GALC activities of the enriched BM 
cells from wild-type and carrier mice. The overall GALC 
activity of these cells was much higher than expected. As 
Table 1 shows the mean GALC activity measured in BM 
cells from wild-type mice, prepared as they are routinely 
prepared for BMT, was 4.4 nmol/h/mg protein, ranging 
between 3.0 and 6.2 nmol/h/mg protein. It was also the 
highest GALC activity of all other organs examined in 
these mice, except for the kidneys where the mean GALC 
activity was 7.8 nmol/h/mg protein. The average GALC 
activity measured in BM cells of the heterozygous mice 
was 2.1 nmol/h/mg protein about half of the values from 
wild-type mice, as expected (Table 1).
BM cells used for GALC assays were prepared as 
described in Materials and Methods. We also assayed 
GALC activity of differentiated monocytes/macrophages 
from wild type mice that were prepared according to the 
method described by Wagner et al.33 GALC activity of 
these cells after being in differentiation media for 5 and 8 
days was 8.4 and 10.1 nmol/h/mg protein. 
Effect of increased viral dose in gene therapy treatment 
alone
Previously, we reported the critical role of viral dose in 
combinational therapy of twi mice.29 Here, we report the 
results of increased viral dose without BMT.
Survival, weight gain, and strength 
Fig. 2A shows the extension of the survival of twi mice 
as the viral dose increases. Using our initially published 
1X viral dose alone the median survival age was 72 days. 
The median survival is 351 days when that viral dose is 
combined with BMT, clearly showing the synergistic effect 
of this combination. However, increasing the viral dose 4X 
without BMT raised the median survival age to about 180 
days. A 10X viral dose without BMT increased the median 
survival age to 280 days without any apparent toxicity. 
Longest living mouse treated with a 10X viral dose at 
PND10 was sacrificed at age 430 days.
Body weights of the treated mice have been monitored 
as an indicator of general health. Fig. 2B shows the growth 
and weight gain of the differently treated mice compared 
to the untreated affected mice and wild-type mice. While 
there is a significant difference in weight gains of the mice 
treated with a combination of 1X AAV plus BMT compared 
to wild-type mice (P<0.0001), there is no significant 
difference between the twi mice receiving 10X AAV alone 
compared to wild-type mice. The lower body weights in 
the mice receiving combined treatment likely reflect the 
effects of the busulfan used for myelosuppression. 
A hanging and grip test, an indicator of strength and 
coordination, was measured in wild-type mice, untreated 
twi mice and affected mice treated with 10X AAVrh10-
mGALC as described in Materials and Methods. Untreated 
twi mice have impaired motor function and are unable to 
complete any hanging test after 3-4 weeks of age. However, 
mice treated with a high viral dose alone, tested between 
250 and 300 days of age, did as well as the wild-type mice 
(Fig. 2C). These mice were able to hang on the inverted 
Fig. 1. Comparison of the survival outcomes from twi mice receiving 
1X viral dose (4 x 1013 gc/kg) plus BM cells from wild-type mice and twi 
mice receiving the same viral dose but BM cells from heterozygote mice. 
Another group of twi mice received BMT from wild-type mice but half of 
the viral dose (2 x 1013 gc/kg). While the survival curves of the treatment 
groups using ½ viral dose or BM cells from carrier mice are not significantly 
different from each other (p=0.9999), the survival curves of these two 
groups are significantly different from the survival curve of mice receiving 
1X viral dose and BM cells from wild-type mice (P < 0.001and P < 0.0001 
respectively).
Treatment of twitcher mice with AAVrh-10GALC alone 
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screen for at least 90 seconds, the maximum time allowed 
for wild-type mice. 
Physical appearance and behavior
All mice treated with a high viral dose alone had normal 
appearance compared to wild-type mice, with no tremor 
or twitching. Some presented mild wobbling at terminal 
age or about a week before death. Mice receiving BMT 
alone or BMT plus viral therapy show side effects probably 
from the busulfan, including ruffled fur and smaller size. 
The mice treated with 10X viral dose alone presented with 
shiny, black coats similar to wild-type mice in addition 
to normal body weight. Fig. 3A shows one such treated 
mouse with two mice that were treated with BMT plus 
viral therapy. Mice treated with the higher viral dose alone, 
demonstrated normal behavior for almost their entire 
life. This included continuous exploratory movements, 
climbing the walls of the cage, and having a normal walking 
pattern. Fig. 3B compares the gait pattern of a 260-day-old 
mouse treated with 10X viral dose alone to an 80-day-
old wild-type mouse and an untreated 42-day-old twi 
mouse. Another major drawback of BMT in the treatment 
of twi mice is the gonadotoxicity of busulfan and other 
myeloablative agents used in the BMT procedure causing 
infertility in male and female mice.38 Similar findings have 
Table 1. GALC activity of different tissues from wild-type and heterozygous mice
Mice age BM Brain Cereb SC SN Liver Heart Muscle Kidney
GALC activity*of different tissues from wild-type mice
70-d 3.0 1.0 0.7 0.3 0.4 1.1 0.4 0.2 9.0
80-d 3.7 0.8 1.0 0.8 0.7 1.6 3.4 0.8 6.5
120-d 4.3 1.7 0.8 1.0 0.8 1.5 0.6 0.4 6.2
80-d 4.2 1.5 NA NA NA NA NA NA 8.9
150-d 5.0 0.6 NA NA NA NA NA NA 8.4
110-d 6.2 1.8 NA NA NA NA NA NA 8.0
Mean values 4.40 1.23 0.83 0.70 0.63 1.36 1.46 0.46 7.83
GALC activity*of different tissues from heterozygote mice
30-d 1.7 1.2 0.8 0.8 0.8 2.1 0.4 0.4 -
45-d 2.1 0.9 1.0 0.7 1.0 1.3 1.3 0.8 3.4
150-d 3.1 1.0 0.9 0.6 0.3 0.9 0.2 0.4 3.2
150-d 2.0 0.7 0.5 0.5 0.1 0.9 0.2 0.7 2.7
218-d 1.8 0.5 0.6 0.1 0.03 1.7 0.1 0.6 2.5
Mean values 2.14 0.86 0.76 0.54 0.44 1.38 0.44 0.58 2.95
* nmol/h/mg protein.
Fig. 2. Comparing various treatments of twi mice for survival, weight gain and strength. (A) Survival of twi mice treated with AAVrh10 alone at different doses 
compared to mice treated with combination therapy and untreated mice. Between 1X and 10X viral dose the survival was highly significant (P < 0.0001). 
Comparing 10X alone and 1X + BMT survival was much less significant (P < 0.05). (B) Weighs of the mice treated with 10X AAVrh10 alone (n=9), 1X + BMT 
(n=16), untreated affected (n=9) and wild type mice (n=4). (C) Hang time of mice treated with 10X AAVrh10 alone (n=2) tested between 250 and 300 days 
compared to untreated affected and wild type mice.
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been reported in human patients receiving HSCT.39 Male 
and female affected twi mice treated with a high viral dose 
alone maintain their full fertility, delivering several litters 
of all affected pups (Fig. 3C). The maturity age and the size 
of the litters are comparable to wild-type mice40 (Fig. 3D). 
Pathological assessment 
Antibodies against CD68, a marker of inflammation, and 
glial fibrillary acidic protein (GFAP) are used to compare 
the brain sections of mice treated with 10X viral dose to 
80-day-old wild-type mouse and 42-day-old untreated 
twi mouse (Figs. 4 and 5). In contrast to the untreated twi 
mouse, the brain sections of the 90-day-old and 76-day-
old AAV-treated mice are free of activated microglial/
macrophages and are comparable to the wild-type mice 
(Fig. 4). In Fig. 5, the sections from the same mice stained 
with the anti-GFAP antibody are shown. As shown in Fig. 
5B, the untreated twi mouse demonstrates an increased 
number of hypertrophic reactive appearing astrocytes. 
The astrocytic densities of the 90-day-old and 76-day-old 
mice treated with 10X viral dose are comparable to the 
wild-type mouse (Fig. 5A). 
Ability of AAVrh10 to transduce certain tissues including 
BM cells following iv injection
We measured the GALC activity in certain tissues, 
including BM cells, from twi mice treated with iv gene 
therapy alone or gene therapy combined with BMT (Table 
2). BM cells from twi mice treated with 10X AAVrh10-
mGALC alone exhibit GALC activity as high or higher 
than mice treated with BMT plus 1X and 4X AAVrh10-
mGALC. GALC expression in these cells could be detected 
48 hours after viral injection and remains persistent during 
the lifespan of the virally treated mice. To our knowledge, 
no published study has described in vivo transduction 
of BM cells by any AAV vector. However, several ex vivo 
studies using different AAV serotypes including AAV1 
and AAV6 have shown a weak transduction of BM cells 
in culture.41-44 When BM cells from heterozygous mice 
are used for transplantation with the 1X viral dose, the 
measured GALC activity in nervous tissues was about half 
of the activity measured when BM cells from wild type 
mice were used with 1X viral dose (Table 3). The activity 
measured is similar to the activity when BM cells from 
wild type mice were used with ½X viral dose. 
Ability of AAVrh10-mGALC to transduce BM cells in 
vitro 
Following the detection of the in vivo transduction of BM 
cells after iv injection of AAVrh10-mGALC, the question 
was whether such ability could be demonstrated in BM 
cells in tissue culture. To this end, the harvested BM cells 
from twi mice were cultured in monocyte isolation media 
(see Materials and Methods). Under such conditions, BM 
cells differentiate towards the monocyte/macrophage 
state.33 The transductions were done by adding 3 x 1010 gc/
mL of AAVrh10-mGALC to the medium and keeping them 
at 37o C in a cell-culture incubator for several days. The 
success of the transduction was determined by evaluating 
the GALC activity of the cells at different time points. 
Increased GALC activity of BM cells could be detected 48 
Fig. 3. Effects of various treatments on physical appearance, gait and fertility. (A) The physical appearance of a mouse treated with the 10X viral dose (middle) 
is compared to age-matched mice (250-days old) treated with 1X viral dose + BMT. While the mice receiving combined therapy are smaller in size and have 
grey fur, the mice treated with the higher viral dose alone have a normal appearance and a normal coat. (B) Footprints of an 80-day-old wild-type mouse (a) 
and a 42-day-old untreated affected mouse (b) and a 260-day-old mouse treated with 10X viral dose (c). (C) The second litter resulting from the mating of 
affected mice treated with 10X viral dose only. All pups are affected since both parents are genetically homozygote for the twi mutation. (D) Reproductive age 
and litter size of female mice treated with 10X viral dose compared to wild-type mice.
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hours after transduction and continued to increase with 
time. The GALC activity of the transduced BM cells from 
twi mice could reach as high as 23.0 nmol/h/mg protein 
after being in culture for 5 days and 46.5 nmol/h/mg 
protein after being in culture for eight days. This may be 
the result of the continuous GALC expression or possibly 
due to expressed GALC being taken up from the cultured 
media according to the cross-correction phenomena 
reported earlier.45 
Effects of anti-inflammatory drugs on the progression of 
the disease
Given that neuro-inflammation is a component of KD, 
HSCT has been recognized as an effective option to lower 
the inflammation by delivering multiple anti-inflammatory 
cytokines. However, as HSCT/BMT comes with undesired 
side effects, we were interested to see if a safe and similarly 
effective option could be found to replace the current 
methodology. To this end indomethacin, a well-known 
non-steroidal anti-inflammatory drug was chosen to 
evaluate its potential in eliminating neuro-inflammation 
and slowing disease progression in combination with 
gene therapy. In a comparative study of several non-
steroidal anti-inflammatory drugs, indomethacin was 
found to decrease the levels of several factors involved in 
inflammation.22 Therefore, following iv injection of a 1X 
viral dose on PND10, indomethacin was also supplied in 
the drinking water with a concentration of 2 ug to 4 ug/
Fig. 4. Staining of activated microglia/macrophages in CNS. Brain sections 
from the 90-day-old (image C) and 76-days-old (image D) twitcher mice 
treated with high viral dose (4x 1014 gc/kg) only are compared to the 
42-day-old untreated twitcher (B) and 80-day-old wild-type mice (A). All 
images are from PFA-fixed frozen sections stained with CD68 antibody. 
No CD68-positive cells were detected in virally treated twi mice (original 
magnification ×400).
Fig. 5. Astrogliosis. All images are from PFA-fixed frozen sections 
stained with anti-glial fibrillary acidic protein (GFAP) antibody that detects 
astrocytes. Image (A) is from a 80-day-old wild-type mouse, image (B) 
from 42-day-old untreated twi, image (C) and (D) from the 90-day-old 
and 76-day-old mice respectively treated with 10X viral dose (all original 
magnifications are ×400). As shown in images (C) and (D), the astrocyte 
distribution is comparable to the wild-type mouse. 
Table 2. GALC activity* in certain tissues from mice treated by different methods
Mice treatment** Brain Sciatic nerve Heart BM cells
BMT + 1X AAV 0.9, 1.4 1.3, 23.0 470.2, 553.7 13.9, 19.8
BMT + 4X AAV 3.0, 3.5 1.8, 4.6 441.0, 515.4 12.1, 13.7
10X AAV only 2.3-5.9 8.6-18.8 488.6-626.9 15.8-44.2
Wild-type 0.6-1.8 0.4-0.8 0.4-3.4 3.0-6.2
Untreated twi 0-0.1 0.1-0.2 0-0.2 0-0.1
* nmol/h/mg protein.
** Two mice analyzed in “BMT + 1X AAV” group were at PND218 and 362, two mice in group “BMT + 4X AAV” were at PND105 and 341 and five mice 
in group “10X AAV alone” were at PND37, 54, 90, 111 and 150.
Table 3. GALC activity in nervous tissues based on BM donor type and viral dose
Treatment Average of GALC activity* n=6-13
BM donor Viral dose Brain Cerebellum Sciatic Nerve
Wild-type mice 1X viral dose 1.7 1.6 5.9
Wild-type mice 1/2X viral dose 0.8 1.0 2.0
Wild-type mice No viral injection 0.9 1.0 1.4
Heterozygote mice 1X viral dose 0.8 1.1 2.7
* nmol/h/mg protein.
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mL starting on PND14 and continued for 4 weeks. No 
tangible positive result was obtained from the total of six 
mice treated this way. Treated mice lived between 54 and 
67 days, which was similar to the treatment with a 1X viral 
dose alone.
BMT using BM cells with supra-normal GALC activity 
Multiple attempts at transplanting in vivo-transduced 
BM cells expressing supra-normal GALC activity failed 
engraftment. The isolated BM cells from twi mice that had 
been treated with a 10X dose of AAV vector had GALC 
activity between 16 and 44 nmol/h/mg protein (Table 2). 
This is well above GALC activity in BM cells of wild type 
mice (Table 1). Transplantation failure was previously 
reported by Gentner et al46 using high GALC-expressing 
BM cells following in vitro transduction by a lentiviral 
vector. As the transplantation failed, they concluded 
that higher than normal GALC activity must be toxic 
for hematopoietic stem cells and early progenitor cells. 
However, following the iv injection of 10X AAVrh10-
mGALC, the GALC activity in BM cells is much higher 
than BM cells from wild type mice (Table 2) yet mice 
treated in this manner live much longer than twi mice 
treated by BMT or with 1X AAVrh10-mGALC alone. This 
indicates that their BM is functioning normally although 
it has very high GALC activity.
Discussion 
KD is caused by the deficiency of GALC activity resulting 
from mutations in the GALC gene. Several animal models, 
including mice, dogs, and rhesus monkeys, have also 
been identified.6-8 The mouse model of this disease has a 
mutation causing a premature stop codon in the GALC 
gene.30 Mice homozygous for this mutation usually die 
between 35 and 45 days. 
BMT treatment of twi mice has resulted in increased 
lifespan as reported by several studies.23-26,28 Some authors 
believe that the effectiveness of BMT is mostly due to 
the ability of the BM cells to deliver GALC activity to 
the critical tissues,25-27 while others consider their anti-
inflammation properties as an additional beneficial 
factor.20,27,28 Adding gene therapy to BMT has resulted in a 
much better outcome as reported by us and others.10,19,20,27-29, 
47 However, the mechanism of such synergistic effect has 
not been clearly understood. As discussed below, the data 
presented in this paper suggest that HSCT/BMT may 
not be necessary for successful treatment of twi mice or 
Krabbe patients if a high dose of viral vector alone is timely 
delivered to the critical tissues. This will result in sufficient 
GALC expression in CNS before the accumulation of toxic 
metabolites that will trigger neuro-inflammation. 
Timing of the pathological damages causing inflammation 
in the CNS of twi mice
Twi mice are indistinguishable from wild-type littermates 
until PND20-21 and have similar immune response 
capability as wild-type mice.48 Neurologic features 
including tremors and ataxic gait appear around day 
20.49 Evidence of hypomyelination in the PNS also 
has been reported around PND15-20.50 The earliest 
changes in microglial morphology was not seen until 
two weeks of age.51 Therefore, twi mice treated with 
BMT may benefit from the anti-inflammatory role of 
the infiltrated macrophages in the CNS only when the 
disease has progressed. The same may be true in affected 
human patients. Supplying enough GALC activity at the 
earlier time, when the mouse or human patient is pre-
symptomatic, could prevent disease progression and avert 
CNS inflammation (Figs. 4 and 5). This can be done by 
GALC-expressing macrophages produced by HSCT/BMT 
or by transducing endogenous macrophages by other 
strategies such as gene therapy. The advantage of in vivo 
virally-transduced macrophages is that they can rapidly 
deliver high GALC activity to degrade myelin debris and 
prevent globoid cell formation. 
As noted in the Results section, the addition of 
indomethacin in the drinking water did not have any 
synergistic effect when these mice were also treated with 
gene therapy. These experiments may indicate the absence 
of neuro-inflammation at the time of the treatment if 
sufficient GALC is delivered to the CNS. Therefore, in 
addition to the anti-inflammatory role of HSCT/BMT 
discussed in our earlier study,22 BMT also supplies some 
GALC activity when combined with viral gene therapy. 
Hence, with earlier delivery of sufficient GALC activity 
there may be less myelin degradation, neuro-inflammation 
and globoid cell formation. 
We have recently shown that a single iv injection of 
AAVrh10-mGALC combined with BMT can result in 
comparable outcomes when implemented between 
PND10 and PND18 in twi mice.29 The most consistent 
outcomes in our experiments are seen when mice are 
treated between PND10 and PND15. A similar pre-
symptomatic period to start treatment may be available 
for human patients. 
In vivo transduction of BM cells
Table 2 shows the increase in GALC activity of BM cells 
following iv injection of AAVrh10-mGALC with or 
without BMT. The GALC activity in BM cells of twi mice 
treated with 10X AAV alone is as high or higher than BM 
cells from twi mice treated with BMT plus 1X or 4X AAV. 
This could indicate that BMT is not needed to deliver 
GALC activity to nervous tissues. While it takes about 
seven days for the macrophages to be differentiated and 
infiltrated in the CNS following BMT,52 it takes less time 
for endogenous BM cells to be transduced following iv 
viral injection and to reach the CNS after differentiation. 
Avoiding the adverse side effects of the myeloablative 
regimens
The undesirable side effects of the myeloablative 
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regimens required for HSCT/BMT are significant. In 
our experiments, all of the mice treated with busulfan 
before BMT have lower body weight, infertility, and 
depigmentation of their fur (Fig. 3). Similar side effects 
of busulfan treatment have also been reported by Yeager 
et al.53 Busulfan and cyclophosphamide are currently 
the most widely used in the myeloablative regimen of 
allogeneic stem cell transplantation in human patients. In 
addition to side effects of these drugs, human transplant 
recipients can also suffer from varying degrees of graft-
versus-host disease.54 As can be seen in Figs. 2 and 3 mice 
treated with high dose gene therapy alone have the same 
weight, normal appearance and fertility as wild type mice. 
Therefore, the use of gene therapy alone at a sufficient 
dose and before neuro-inflammation has occurred may 
replace the need for blood stem cell transplantation. 
Delivery of GALC activity to twi mice via gene therapy 
versus BMT 
In the present study, we measured the GALC activity in 
certain tissues, including BM cells, in wild type mice, 
untreated twi mice as well as twi mice treated with 
combined therapy and 10X viral gene therapy alone (Table 
2). Clearly, the BM cells of twi mice treated with gene 
therapy have higher GALC activity than wild type mice. 
Our recent publication29 showed that mice treated 
with BM cells from heterozygous mice plus 1X viral 
dose had decreased survival compared to when BM cells 
from wild-type mice were used. This suggested that BM 
cells from wild type mice were delivering more GALC 
activity to critical tissues. This is borne out by the data 
shown in Table 3. While the anti-inflammatory cytokines 
delivered by BM cells from wild-type and heterozygote 
mice should be similar, the GALC activity of BM cells 
from heterozygote mice is about half of the value from 
wild-type mice (Table 1). As shown in Fig. 1 the survival 
curve of these mice is comparable to the survival of the 
mice receiving BMT from wild-type mice but injected 
with1/2X viral dose. The GALC activity measured in the 
CNS of mice treated with a 1X viral dose plus BM cells 
from wild-type mice is higher than in mice treated with 
BM cells from wild type mice alone and mice treated 
with 1X viral dose and BM cells from heterozygous mice 
(Table 3). Therefore, GALC activity in nervous tissues of 
twi mice treated with combined therapy comes from both 
the viral vector transducing endogenous brain cells and 
macrophages recruited from the blood after BMT. 
There appeared to be a failure of engraftment into 
twi mice when isolated BM cells expressing high GALC 
activity following iv AAVrh10-mGALC injection were 
used for transplantation. As mentioned in the Results 
section, similar transplantation failure was also reported 
by Gentner et al46 when the authors used lentvirally-
transduced BM cells with supra-normal GALC activity. 
The authors’ interpretation was that higher than normal 
GALC activity may be toxic for hematopoietic stem cells 
and early progenitor cells. Suppressing GALC expression 
in these cells via incorporation of the miR-126 sequence 
in the viral vector resulted in a successful transplantation. 
However, average survival with this treatment was only 88 
days. In our experiments, all of the treatment approaches 
involving iv injection of AAVrh10-mGALC have resulted 
in higher than normal GALC expression in BM cells of 
the treated mice (Table 2) with no apparent toxicity. The 
reason for unsuccessful transplantation using BM cells 
over-expressing GALC activity may be caused by the 
bone structure and BM niche composition. As reported 
by Katayama and Frenette,55 galcer, the main substrate 
for GALC enzyme, plays an essential role in BM niche 
structure and function. These authors have shown that 
galcer is crucial in establishing lymphoid-supportive 
niches and differentiation of lymphoid precursor cells in 
the BM. The synthesis of galcer is initiated by the addition 
of UDP-galactose to ceramide in a reaction catalyzed by 
UDP-galactose: ceramide galactosyltransferase (CGT). 
As shown by Katayama and colleagues, CGT-deficient 
mice lacking galcer exhibit aberrant nerve conduction 
and disturbed BM niche function.56 In the case of 
supra-normal GALC expression, destruction of the BM 
niches via hydrolyzing BM galcer, could affect the BM’s 
engraftment. Interestingly, blocking GALC expression 
by “stem cell-specific miRNAs” enabled transplantation, 
not by preventing the cellular apoptosis caused by GALC 
toxicity, but by safeguarding the BM niches’ functionality 
and allowing engraftment.46 
Given that the mice treated with a 10X viral dose alone 
benefitted from an extension of healthy and active life, one 
can reasonably conclude that any treatment strategy must 
deliver an adequate amount of missing enzyme to the 
CNS and the PNS before pathology has occurred. Unlike 
the mice treated with a combination of gene therapy and 
BMT, these mice are fertile and capable of delivering 
several litters with up to nine pups in each litter. All of 
these pups are genetically affected when both parents are 
affected and treated with gene therapy alone. 
It is noteworthy that current gene therapy research 
suggests that AAVrh10 and AAV9 are the most efficient 
viral vectors in crossing the BBB.57 However, following 
systemic injection an overwhelming number of viral 
particles are trapped in peripheral organs and only a small 
fraction may reach the CNS and PNS. In the absence of 
an ideal viral vector with higher capability of crossing 
the BBB and transducing the critical cells, one practical 
way of eliminating BMT is by raising the viral dose. As 
demonstrated in this study, the iv injection of 4 ×1014 gc/kg 
body weight of AAVrh10-mGALC, has been tolerated very 
well in the mouse model of GLD with very encouraging 
outcomes and no apparent evidence of toxicity. Perhaps 
the viral dose may be increased even further without 
any toxicity. In support of the presented data, other 
recent publications have shown significant correction of 
neurologic disease using gene therapy alone without BM 
Rafi et al
BioImpacts, 2021, 11(2), 135-146144
cell transplantation. When high dose AAV9 is injected 
intrathecally at an early time point, there is a significant 
extension of life in the dog model of KD without the need 
for BMT.58 Previously, a single iv injection of rAAV vector 
containing aspartoacylase cDNA alone at an early age, 
showed significant effectiveness in treating the mouse 
model of Canavan disease.59 Also, a single iv injection of 
a self-complementary AAV9 vector expressing the Hexb 
cDNA in Sandhoff disease mice has also been shown to be 
safe, prevent disease development and result in a normal 
lifspan.60 However, some recent studies have documented 
the deaths of patients who received high-dose AAV gene 
therapy.61 It should be noted that the patients who died 
following high-dose gene therapy had different diseases 
and pre-existing liver disease and were treated with 
different AAV vectors. While some pathological changes 
were documented in the livers of twi mice treated with 
combined BMT plus iv AAVrh10-mGALC, there was no 
evidence of neoplastic changes.29 In conclusion, it appears 
that AAVrh10-mGALC injected iv at a high enough dose 
before significant pathology has taken place has the ability 
to deliver GALC activity to the CNS and PNS without the 
need for BMT/HSCT and to extend life without the side 
effects of HSCT. With further study, it may be possible to 
safely treat human patients with KD using only viral gene 
therapy. 
Conclusion
Previous studies have shown that BMT together with a 
single intra-venous injection of AAVrh10-GALC results in 
a much better outcome than either treatment alone in twi 
mice. Those studies also showed that timing and dosing 
is critical to a successful outcome. It has been postulated 
that BM cells provide some GALC activity to many tissues 
as well providing an anti-inflammatory component to 
the treatment. The addition of the viral vector results in 
higher GALC activity being expressed in many tissues, 
including the central and peripheral nervous systems, 
leading to much improved myelination and greatly 
extended life in treated mice. As the drugs used for myelo-
suppression before BMT have significant side effects, it 
was considered that the early injection of high dose viral 
vector alone could prevent the inflammatory component 
of this disease and therefore eliminate the need for BMT. 
The results show that when a viral dose of 4 ×1014 gc/kg is 
injected at PND10 there is a significant extension of life, 
about 7 times that of untreated mice, normal appearance 
and strength and normal fertility. In addition there is 
much less activated microglia/macrophages indicating less 
inflammation and less astrogliosis. These studies indicate 
that it may be possible to treat patients with KD with high 
dose viral vector alone without the need for blood stem 
cell transplantation and the drugs used in that therapy.
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What is the current knowledge?
√ KD is an autosomal recessive lysosomal disorder.
√ KD is caused by mutations in the GALC gene.
√ Low GALC activity causes defective myelination in the 
peripheral and central nervous systems.
√ HSCT in pre-symptomatic human patients is the only 
effective treatment at this time.
√ The twi mouse is a useful model to study pathogenesis and 
treatment of KD. 
√ BMT has shown to have a synergistic effect when combined 
with other treatment strategies such as gene therapy in the 
animal models. 
What is new here?
√ Intra-venous (iv) injection of AAVrh10-mGALC gene alone 
at a sufficient viral dose and before neuro-inflammation has 
occurred resulted in extended normal life in twi mice.
√ Iv AAvrh10 gene therapy alone raised GALC activity in 
heart, brain, sciatic nerve and BM cells. 
√ BM cells with high GALC activity from in vivo transduction 
were not successful in treating twi mice when used for BMT. 
√ With further study, this approach may eliminate the need 
for HSCT and its side effects in human patients.
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